LZM012 not checked

Livzon Pharmaceutical Group Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Recombinant anti-human IL-17A/F humanized monoclonal antibody injection”In the company’s words, NCT06110676 on ClinicalTrials.gov
Tested for
Psoriasis (2 trials)
Main trialPhase 3
“This study is a muti-center, randomized, double blind, positive control phase III clinical study to evaluate the efficacy and safety of LZM012 in moderate to severe chronic plaque psoriasis patients”In the company’s words, NCT06110676 on ClinicalTrials.gov

Other drugs for Psoriasis

All 41 drugs for Psoriasis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Unknown Apr 2025 A Study to Evaluate the Efficacy and Safety of LZM012
Phase 3Completed 26 Jan 2026 A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow LZM012

Following is part of Solo: you see every change to LZM012 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in